XASXNOX
Market cap15mUSD
Jan 09, Last price
0.09AUD
1D
-3.37%
1Q
-21.82%
Jan 2017
-79.52%
IPO
-54.74%
Name
Noxopharm Ltd
Chart & Performance
P/E
—
P/S
10.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.16%
Rev. gr., 5y
-8.54%
Revenues
2m
-60.06%
Net income
-4m
L-76.24%
CFO
-684k
L-93.75%
Earnings
Feb 25, 2025
Profile
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑03 | |
| Income | |||||||||
Revenues | 2,400 -60.06% | 6,010 10.71% | 5,429 -3.20% | ||||||
Cost of revenue | 6,969 | 12,470 | 9,808 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (4,569) | (6,460) | (4,379) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (2,400) | (5,985) | (5,368) | ||||||
Tax Rate | |||||||||
NOPAT | (2,169) | (475) | 988 | ||||||
Net income | (3,578) -76.24% | (15,056) -19.34% | (18,667) 99.71% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,205 | ||||||||
BB yield | -2.12% | ||||||||
| Debt | |||||||||
Debt current | 161 | ||||||||
Long-term debt | 161 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 42 | 93 | 195 | ||||||
Net debt | (4,330) | (3,971) | (19,228) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (684) | (10,946) | (13,734) | ||||||
CAPEX | 5 | ||||||||
Cash from investing activities | 124 | ||||||||
Cash from financing activities | (178) | 976 | |||||||
FCF | 1,819 | (746) | (3,452) | ||||||
| Balance | |||||||||
Cash | 2,320 | 3,009 | 14,011 | ||||||
Long term investments | 2,010 | 962 | 5,539 | ||||||
Excess cash | 4,210 | 3,670 | 19,278 | ||||||
Stockholders' equity | 5,495 | 9,073 | 24,118 | ||||||
Invested Capital | 1,328 | 5,496 | 5,196 | ||||||
ROIC | 34.69% | ||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 292,238 | 292,238 | 291,222 | ||||||
Price | 0.07 53.49% | 0.04 -77.95% | 0.20 -69.77% | ||||||
Market cap | 19,288 53.49% | 12,566 -77.87% | 56,788 -66.63% | ||||||
EV | 14,958 | 8,596 | 37,560 | ||||||
EBITDA | (4,567) | (6,306) | (4,118) | ||||||
EV/EBITDA | |||||||||
Interest | 31 | 41 | 77 | ||||||
Interest/NOPBT | |||||||||